Metfogamma

Metformin, the active ingredient in Metfogamma, is a biguanide presented as an oral tablet for oral administration. It reduces hepatic glucose production and improves peripheral insulin sensitivity, providing glycemic control for adults with type 2 diabetes mellitus.

GNH USA supplies Metfogamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering reliable global distribution.

Metfogamma (metformin) is used to manage disorders of glucose metabolism, primarily within the type 2 diabetes therapeutic pathway.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome (PCOS): may improve insulin resistance and restore ovulatory function in affected women.

Metfogamma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient metallic sensation in the mouth. - Loss of appetite: reduced desire to eat. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: liver enzyme elevations. - Hypoglycemia: when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas. - Anemia: due to reduced red blood cell production.

Before initiating Metfogamma, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

- Renal function: assess creatinine clearance; avoid in severe renal impairment. - Hepatic disease: use with caution in patients with liver dysfunction. - Contrast imaging: discontinue before iodinated contrast procedures to reduce lactic acidosis risk. - Alcohol consumption: limit intake as it may potentiate lactic acidosis. - Elderly patients: start at lower doses and monitor for gastrointestinal intolerance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metfogamma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: can affect renal function, requiring dose adjustment. - Diuretics: may increase risk of dehydration and renal impairment. - Other oral hypoglycemics: may potentiate hypoglycemia. - Warfarin: may require INR monitoring due to potential interaction.